IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v8y2008i2p95-106.html
   My bibliography  Save this article

The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments

Author

Listed:
  • G. Kobelt
  • B. Jönsson

Abstract

No abstract is available for this item.

Suggested Citation

  • G. Kobelt & B. Jönsson, 2008. "The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 95-106, January.
    • Handle: RePEc:spr:eujhec:v:8:y:2008:i:2:p:95-106
    DOI: 10.1007/s10198-007-0091-0
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10198-007-0091-0
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s10198-007-0091-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Torrance, George W., 1986. "Measurement of health state utilities for economic appraisal : A review," Journal of Health Economics, Elsevier, vol. 5(1), pages 1-30, March.
    2. Brazier, John & Roberts, Jennifer & Deverill, Mark, 2002. "The estimation of a preference-based measure of health from the SF-36," Journal of Health Economics, Elsevier, vol. 21(2), pages 271-292, March.
    3. Paul Dolan & Claire Gudex & Paul Kind & Alan Williams, 1995. "A social tariff for EuroQol: results from a UK general population survey," Working Papers 138chedp, Centre for Health Economics, University of York.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Azucena Pedraz-Marcos & Ana María Palmar-Santos & Claire Anne Hale & Juan Zarco-Colón & Milagros Ramasco-Gutiérrez & Eva García-Perea & Teresa Velasco-Ripoll & Josefina Martín-Alarcón & Nuria Sa, 2020. "Living With Rheumatoid Arthritis in Spain: A Qualitative Study of Patient Experience and the Role of Health Professionals," Clinical Nursing Research, , vol. 29(8), pages 551-560, November.
    2. Sonja Merkesdal & Timm Kirchhoff & Diane Wolka & Gunter Ladinek & Adrian Kielhorn & Andrea Rubbert-Roth, 2010. "Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(1), pages 95-104, February.
    3. Márta Péntek & László Gulácsi & Bernadette Rojkovich & Valentin Brodszky & Job Exel & Werner Brouwer, 2014. "Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 83-92, May.
    4. Bogdan Batko & Paulina Rolska-Wójcik & Magdalena Władysiuk, 2019. "Indirect Costs of Rheumatoid Arthritis Depending on Type of Treatment—A Systematic Literature Review," IJERPH, MDPI, vol. 16(16), pages 1-16, August.
    5. Kurt Brekke & Dag Dalen & Tor Holmås, 2014. "Diffusion of pharmaceuticals: cross-country evidence of anti-TNF drugs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 937-951, December.
    6. Benjamin Birkner & Jürgen Rech & Tom Stargardt, 2020. "Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis," PLOS ONE, Public Library of Science, vol. 15(1), pages 1-17, January.
    7. Evo Alemao & Maiwenn J Al & Annelies A Boonen & Matthew D Stevenson & Suzanne M M Verstappen & Kaleb Michaud & Michael E Weinblatt & Maureen P M H Rutten-van Mölken, 2018. "Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-18, October.
    8. Karine Chevreul & Georges Haour & Sandy Lucier & Stephanie Harvard & Marie-Laure Laroche & Xavier Mariette & Alain Saraux & Isabelle Durand-Zaleski & Francis Guillemin & Bruno Fautrel, 2014. "Evolution of Direct Costs in the First Years of Rheumatoid Arthritis: Impact of Early versus Late Biologic Initiation - An Economic Analysis Based on the ESPOIR Cohort," PLOS ONE, Public Library of Science, vol. 9(5), pages 1-9, May.
    9. László Gulácsi, 2010. "Future challenges for health economics and health technology assessment of biological drugs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(3), pages 235-238, June.
    10. Márta Péntek & Gyula Poór & Piotr Wiland & Martina Olejárová & Marek Brzosko & Catalin Codreanu & Nóra Brodszky & László Gulácsi, 2014. "Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 35-43, May.
    11. Ulf Persson, 2012. "Value Based Pricing in Sweden: Lessons for Design?," Seminar Briefing 000141, Office of Health Economics.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Garry R. Barton & Tracey H. Sach & Anthony J. Avery & Claire Jenkinson & Michael Doherty & David K. Whynes & Kenneth R. Muir, 2008. "A comparison of the performance of the EQ‐5D and SF‐6D for individuals aged ≥ 45 years," Health Economics, John Wiley & Sons, Ltd., vol. 17(7), pages 815-832, July.
    2. Garry Barton & Tracey Sach & Michael Doherty & Anthony Avery & Claire Jenkinson & Kenneth Muir, 2008. "An assessment of the discriminative ability of the EQ-5D index , SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(3), pages 237-249, August.
    3. Nick Bansback & Huiying Sun & Daphne P. Guh & Xin Li & Bohdan Nosyk & Susan Griffin & Paul G. Barnett & Aslam H. Anis, 2008. "Impact of the recall period on measuring health utilities for acute events," Health Economics, John Wiley & Sons, Ltd., vol. 17(12), pages 1413-1419.
    4. McCabe, Christopher & Brazier, John & Gilks, Peter & Tsuchiya, Aki & Roberts, Jennifer & O'Hagan, Anthony & Stevens, Katherine, 2006. "Using rank data to estimate health state utility models," Journal of Health Economics, Elsevier, vol. 25(3), pages 418-431, May.
    5. P. Wang & M. Li & G. Liu & J. Thumboo & N. Luo, 2015. "Do Chinese have similar health-state preferences? A comparison of mainland Chinese and Singaporean Chinese," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(8), pages 857-863, November.
    6. Erika Laranjeira & Helena Szrek, 2016. "Going beyond life expectancy in assessments of health systems’ performance: life expectancy adjusted by perceived health status," International Journal of Health Economics and Management, Springer, vol. 16(2), pages 133-161, June.
    7. Carmen Selva-Sevilla & Paula Ferrara & Manuel Gerónimo-Pardo, 2020. "Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(4), pages 649-662, June.
    8. W. Greiner & C. Claes & J. J. V. Busschbach & J.-M. Schulenburg, 2005. "Validating the EQ-5D with time trade off for the German population," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(2), pages 124-130, June.
    9. Richard Holland & Richard D Smith & Ian Harvey & Louise Swift & Elizabeth Lenaghan, 2004. "Assessing quality of life in the elderly: a direct comparison of the EQ‐5D and AQoL," Health Economics, John Wiley & Sons, Ltd., vol. 13(8), pages 793-805, August.
    10. McCabe, C & Brazier, J & Gilks, P & Tsuchiya, A & Roberts, J & O'Hagan, A & Stevens, K, 2004. "Estimating population cardinal health state valuation models from individual ordinal (rank) health state preference data," MPRA Paper 29759, University Library of Munich, Germany.
    11. David Feeny, 2012. "The Multi-attribute Utility Approach to Assessing Health-related Quality of Life," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 36, Edward Elgar Publishing.
    12. Karen Gerard & Katharine Johnston & Jackie Brown, 1999. "The role of a pre‐scored multi‐attribute health classification measure in validating condition‐specific health state descriptions," Health Economics, John Wiley & Sons, Ltd., vol. 8(8), pages 685-699, December.
    13. Bernie J. O'Brien & Marian Spath & Gordon Blackhouse & J.L. Severens & Paul Dorian & John Brazier, 2003. "A view from the bridge: agreement between the SF‐6D utility algorithm and the Health Utilities Index," Health Economics, John Wiley & Sons, Ltd., vol. 12(11), pages 975-981, November.
    14. D. Stratmann‐Schoene & T. Kuehn & R. Kreienberg & R. Leidl, 2006. "A preference‐based index for the SF‐12," Health Economics, John Wiley & Sons, Ltd., vol. 15(6), pages 553-564, June.
    15. Stavros Petrou & Christine Hockley, 2005. "An investigation into the empirical validity of the EQ‐5D and SF‐6D based on hypothetical preferences in a general population," Health Economics, John Wiley & Sons, Ltd., vol. 14(11), pages 1169-1189, November.
    16. Dolan, Paul & Kavetsos, Georgios & Tsuchiya, Aki, 2013. "Sick but satisfied: The impact of life and health satisfaction on choice between health scenarios," Journal of Health Economics, Elsevier, vol. 32(4), pages 708-714.
    17. Eva Rodríguez Míguez & José María Abellán Perpiñán & José Carlos Álvarez Villamarín & José Manuel González Martínez & Antonio Rodríguez Sampayo, 2013. "Development of a new preference-based instrument to measure dependency," Working Papers 1301, Universidade de Vigo, Departamento de Economía Aplicada.
    18. Benjamin M. Craig & Jan J. V. Busschbach, 2011. "Toward a more universal approach in health valuation," Health Economics, John Wiley & Sons, Ltd., vol. 20(7), pages 864-875, July.
    19. Christine McDonough & Anna Tosteson, 2007. "Measuring Preferences for Cost-Utility Analysis," PharmacoEconomics, Springer, vol. 25(2), pages 93-106, February.
    20. Matthijs M. Versteegh & Annemieke Leunis & Jolanda J. Luime & Mike Boggild & Carin A. Uyl-de Groot & Elly A. Stolk, 2012. "Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D," Medical Decision Making, , vol. 32(4), pages 554-568, July.

    More about this item

    Keywords

    Rheumatoid arthritis; Cost-effectiveness; Modeling; I11;
    All these keywords.

    JEL classification:

    • I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:8:y:2008:i:2:p:95-106. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.